To The ediTor:
Walczyk et al described a "probable" case of serotonin syndrome (SS), which they attributed to tapentadol overdose. 1 However, they bolster their conclusion with a misread of the literature and a faulty use of the Naranjo score.
First, the patient clearly had an opioid toxidrome (unconsciousness, mydriasis, respiratory depression, and brisk response to naloxone). The clinical description after the naloxone administration lacks a compelling description of SS, and the patient does not meet the Hunter criteria (named for a location and not a person). 2 The tachycardia, hypertension, and agitation are not specific for SS. Opioid withdrawal is a more likely cause of his symptoms after naloxone reversal. The authors do not describe the tremor or hyperreflexia after mentioning them only once. The patient did not receive treatment tailored to SS, but instead he received aggressive sedation with 8 mg of lorazepam, 10 mg of haloperidol, and 50 mg of diphenhydramine.
Second, assuming that he was experiencing SS, the co-ingestion of amitriptyline and duloxetine would have been sufficient to explain SS. It is impossible to conclude that tapentadol was the principal cause of SS, if it actually occurred.
Third, the authors misrepresent the prior case cited to support SS caused by tapentadol. Franco et al described the postmortem findings of a 40-year-old man found dead 3 days after anyone last saw him alive. 3 There were no observations to support SS. He had an apparent overdose of tapentadol 75 mg (21 tablets missing), escitalopram 20 mg (10 tablets missing), and amitriptyline 100 mg (4 tablets missing). His heart blood tapentadol concentration was 6,600 ng/mL (>20 times the upper limit of the therapeutic range [5-300 ng/mL]).
Perhaps the only convincing published case of SS with tapentadol was a MedWatch case that involved venlafaxine. 4 From this case, it is impossible to assign greater blame to tapentadol than to venlafaxine.
Finally, the Naranjo score is not designed for proving a toxic effect. 5 Naranjo and colleagues devised the checklist to reduce interobserver variability among pharmacists assessing suspected adverse drug reactions. 6 However, Naranjo et al specfically excluded intentional or accidental poisoning and drug abuse. 5, 6 Even if it were useful in understanding the present case, the authors have calculated this incorrectly. We find that the maximum score is 1 ( Table 1) , which falls at the bottom the "possible" range.
In summary, there is insufficient evidence to assert that SS occurred in this case and to blame tapentadol primarily for any observed symptoms. Note: ADR = adverse drug reaction; SS = serotonin syndrome. 
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